This document discusses the development of syndromic practice guidelines for primary care in high HIV prevalence settings. It argues that standardized case management can improve diagnosis, treatment, and referral. Common outpatient conditions like respiratory infections, malaria, and STIs represent a large portion of health service visits. While disease presentations in early stage HIV may not differ from non-infected individuals, adequate management of selected conditions can reduce mortality and improve quality of life for those with HIV. Further research is still needed on treating certain conditions like pneumonia to help develop standardized syndromic guidelines.
Dr. Eric Lugada. M.B.Ch.B, PhD Medical Epidemiologist. Transformational leader in the global/public health. Program Director - Department of Defence HIV/AIDS Prevention Program (DHAPP) Uganda. University Research Co., LLC (URC) and Center for Human Services (CHS), Kampala, Uganda.
October 7, 2019
On October 7, 2019, the Harvard Global Health Institute will host a one-day symposium to explore what enabled this visionary program, and to showcase how it has transformed not just the worldwide HIV/AIDS response but global health delivery more broadly.
There are many lessons learned in PEPFAR’s story - from what it took to build a supply chain where there was none, to establishing the use of generic antiretroviral therapies (ARTs) and leveraging human capacity. This event convened the early architects of PEPFAR as well as experts and implementers currently leading the charge. We took a historically informed look at what it will take to stop global transmission, and shared tools useful for others hoping to move the needle on vexing problems in global health.
For more information, visit our website at https://petrieflom.law.harvard.edu/events/details/15-years-of-pepfar
Behavioral Health Navigator Presentation by Emerson Evans 12-12-13Office of HIV Planning
Emerson Evans (AACO) presented on a SAMHSA-funded behavioral health navigator program on 12-12-13. This program in Philadelphia was discussed with the Philadelphia EMA Ryan White Part A Planning Council.
Innovation in Surveillance of Communicable and Non-Communicable DiseasesDr. Nirmal Kandel
Innovation in Surveillance of Communicable and Non-communicable Diseases
http://nirmalkandel.com/wp-content/uploads/2014/03/Innovation-in-Surveillance.pdf
As COVID-19 continues to affect individuals around the globe, we want to gain a deeper understanding of how the illness impacts IBD patients. That's why researchers created SECURE-IBD, an international pediatric and adult IBD database to monitor and report on outcomes of COVID-19 occurring in IBD patients. This slide deck provides updates on the SECURE-IBD registry as of April 15, 2020.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Mika Salminen, European HA-REACT project
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Dr. Eric Lugada. M.B.Ch.B, PhD Medical Epidemiologist. Transformational leader in the global/public health. Program Director - Department of Defence HIV/AIDS Prevention Program (DHAPP) Uganda. University Research Co., LLC (URC) and Center for Human Services (CHS), Kampala, Uganda.
October 7, 2019
On October 7, 2019, the Harvard Global Health Institute will host a one-day symposium to explore what enabled this visionary program, and to showcase how it has transformed not just the worldwide HIV/AIDS response but global health delivery more broadly.
There are many lessons learned in PEPFAR’s story - from what it took to build a supply chain where there was none, to establishing the use of generic antiretroviral therapies (ARTs) and leveraging human capacity. This event convened the early architects of PEPFAR as well as experts and implementers currently leading the charge. We took a historically informed look at what it will take to stop global transmission, and shared tools useful for others hoping to move the needle on vexing problems in global health.
For more information, visit our website at https://petrieflom.law.harvard.edu/events/details/15-years-of-pepfar
Behavioral Health Navigator Presentation by Emerson Evans 12-12-13Office of HIV Planning
Emerson Evans (AACO) presented on a SAMHSA-funded behavioral health navigator program on 12-12-13. This program in Philadelphia was discussed with the Philadelphia EMA Ryan White Part A Planning Council.
Innovation in Surveillance of Communicable and Non-Communicable DiseasesDr. Nirmal Kandel
Innovation in Surveillance of Communicable and Non-communicable Diseases
http://nirmalkandel.com/wp-content/uploads/2014/03/Innovation-in-Surveillance.pdf
As COVID-19 continues to affect individuals around the globe, we want to gain a deeper understanding of how the illness impacts IBD patients. That's why researchers created SECURE-IBD, an international pediatric and adult IBD database to monitor and report on outcomes of COVID-19 occurring in IBD patients. This slide deck provides updates on the SECURE-IBD registry as of April 15, 2020.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Mika Salminen, European HA-REACT project
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Valerie Delpech, Public Health Engand
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
In this global pandemic, IBD patients and their healthcare providers from around the world share similar fears and concerns. SECURE-IBD is an international database to monitor and report on COVID-19 in IBD patients. By working across borders, we are learning how factors like age, other conditions, and IBD treatments impact COVID-19 outcomes. This slide deck also shares information about other research efforts that are ongoing to better understand the impact of COVID-19 on IBD patients.
The Foundation would like to thank AbbVie Inc., Genentech, Inc., Gilead Sciences, Inc., Janssen Biotech, Inc., Shire, and Takeda Pharmaceuticals U.S.A., Inc., sponsors of our COVID-19 materials. Additional support is provided through the Foundation’s annual giving program and individual donors.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Sophocles Chanos
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Cary James, Terrence Higgins Trust
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Valerie Delpech, Public Health Engand
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
In this global pandemic, IBD patients and their healthcare providers from around the world share similar fears and concerns. SECURE-IBD is an international database to monitor and report on COVID-19 in IBD patients. By working across borders, we are learning how factors like age, other conditions, and IBD treatments impact COVID-19 outcomes. This slide deck also shares information about other research efforts that are ongoing to better understand the impact of COVID-19 on IBD patients.
The Foundation would like to thank AbbVie Inc., Genentech, Inc., Gilead Sciences, Inc., Janssen Biotech, Inc., Shire, and Takeda Pharmaceuticals U.S.A., Inc., sponsors of our COVID-19 materials. Additional support is provided through the Foundation’s annual giving program and individual donors.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Sophocles Chanos
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Cary James, Terrence Higgins Trust
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Community Based Treatment Support Services: The Treatment Support Arm of the ...jehill3
Community Based Treatment Support Services: The Treatment Support Arm of the AIDSRelief Program
Martine Etienne, UMSOM-IHV/AIDSRelief
HIV/AIDS Working Group Showcase
CORE Group Spring Meeting, April 29, 2010
This presentation discusses:
Why it is a Global Health Issue?
Difference between HIV and AIDS?
Signs and Symptoms
Routes of Transmission
Risk factors
Diagnosis
Prevention
Treatment
People Living with Human Immunodeficiency Virus in Hadhramout: Clinical Prese...asclepiuspdfs
The objective of the study was to determine the clinical features and outcome of patients living with human immunodeficiency virus (HIV) in Hadhramout and nearby governorates. Materials and Methods: This descriptive study was conducted in the antiretroviral therapy (ART) site at Ibn-Sina General Hospital, Mukalla, Hadhramout governorate. All 145 patients were enrolled in HIV treatment and care program from December 2008 to the end of December 2016 with confirmed HIV test. Data included all personal data, clinical staging, drugs taken, and outcomes. Patients were grouped according to the decades to five groups, ≤15 years, 16–30 years, 31–50 years, 51–70 years, and >70 years. Cases classify according to the antiretroviral drugs to ART group and Pre-ART group. The relevant data parameters were analyzed using SPSS statistical software version 21 and Excel 10. Results: A total of 145 cases, most adults (97.9%), males and females were104 (71.7%) and 41 (28.3%), respectively. Mean age was 36.46 years and 30–50 years the most affected age group (55.2%). Clinical Stages 3 and 4 were the common presentation in 73.8%, and most cases were from Mukalla city. Of the total cases, 74.5% were on ART 53.1 of them improved, pulmonary tuberculosis was found in 4 cases, and death cases were (18.5%), mostly due to late presentation and non-adherence, and mostly occurred in early 6 months of starting the ART. 37 patients were in a pre-treatment group (21.6%), where the mortality rate is 35.1%, mainly due to loss of follow-up. Conclusions: Most cases were adult males, young age and have had late presentation, where mortality is higher in the pre-treatment group due to loss of follow-up and in early 6 months of treatment.
ARV Therapy and the Role of Early Intervention presented by Dr. Rachel Baden, Harvard Medical Faculty Physician at the Fenway Health Center community education conference: An End To AIDS - How A State Bill Can Change Everything hosted by SearchForACure.org, the Fenway Health Center, and the MA Dept. of Public Health
WHO statistics indicate that Over 340 million curable and many
more incurable STIs occur each year among women worldwide and that
Non-sexually-transmitted RTIs are even more common. Failure to diagnose
and treat STIs/RTIs at an early stage may result into serious complications
and consequences including infertility, fetal wastage, ectopic pregnancy,
anogenital cancer, premature delivery, as well as neonatal and infant
infections. Proper management of STIs/RTIs also reduce the maternal and
infant mortality. STIs are also known to enhance the spread of HIV infection
in communities. STIs/ RTIs also have negative socio economic impact that
include, increase cost for health service, relationship/ marriage problems
etc.
Factors Associated with patients adherence to Tb treatment following COVI-19 ...MtMt37
studies show that, Poor adherence to treatment is one of the major challenges affecting tuberculosis control and account for the major obstacles to treatment management . Uganda had a TB default rate of 11% with a treatment success rate of only 70% among smear positive patients (WHO, 2010), compared with national accepted adherence level of 95% of as per the WHO guidelines. It is on record that, Masaka District has high prevalence of TB known to be associated with HIV/AIDs (NTRL 2016). an institutional based survey established among other factors that, inadequate and irregular supplies of TB drugs, long travel distance by patients, stigma, discrimination and suspension of transport as COVID 19 prevention guideline have contributed to poor adherence of TB patients in Masaka.
11. Diagram demonstrating CD4 count for different diagnoses Asympto Feb Illness Upper RTI Pneumo Vag cand UTI STI Folliculitis Oral cand Chronic diarh Diagnoses associated with immunosuppression 0 500 1000 1500 CD4 Count
12. Excess mortality in the era of HIV Age specific mortality rates for diarrhea in 1983 and 1995 Age groups 1983 1995 Deaths per 1000 population
13. Existing evidence that treatment is important Pelvic inflammatory disease Cohen, et al. 1997 & Bukusi et al. 1998 Bacterial pneumonia Gilks, et al. 1996 Tuberculosis Ackah, et al. 1995 Strengthen Health Care System Mwanza STI study: reduced HIV incidence Grosskurth, et al. 1995 Reduced mortality in hospitalized HIV patients Arthur, et al. 2000 40% HIV presumably died of 1 st OI Sewankambo, et al. 2000 Evidence Response to treatment in HIV infected persons
14. Survival of cohort in Nairobi who received primary health care, compared by initial CD4 count Gap: No comparison group with “usual” access to care
15.
16.
17. Gaps in knowledge of treatment efficacy Pneumonia Acute bronchitis Sinusitis Dermatoses Folliculitis Chronic diarrhea
18. Research & development of evaluation indicators and process Clinical outcome Referral pattern & rate of hospitalization Incidence of OIs Survival Validation indicators Cost of care Quality of life